ANI Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited consolidated results. ANI develops, manufactures, and markets generic, established-brand, and rare-disease pharmaceuticals. Its rare-disease business currently consists of Cortrophin Gel.
Key financial results
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Net revenue | $137.4 million | $106.8 million |
| Operating income | $20.3 million | $9.9 million |
| Net income | $18.2 million | $1.4 million |
| Diluted EPS | $0.82 | $0.06 |
| Operating cash flow | $18.3 million | $21.4 million |
- Revenue rose 28.7%. Rare-disease revenue, all from Cortrophin Gel, increased 126.2% to $36.9 million. Generics revenue rose 10.2% to $70.2 million; established brands, royalties, and services rose 13.2% to $30.3 million.
- Cost of sales excluding depreciation and amortization was 35.8% of revenue, versus 35.3% a year earlier. Operating margin was 14.8%, versus 9.2%; reported net margin was 13.3%, versus 1.3%.
- Cash and cash equivalents were $228.6 million at quarter-end, up from $221.1 million at year-end. Current assets were $540.6 million and current liabilities $136.9 million.
- Term-loan principal was $293.3 million; the balance-sheet carrying amount of debt, net of financing costs, was $285.5 million. The term-loan rate was 11.44%. The $40 million revolving facility was undrawn and available subject to conditions. Cash exceeded term-loan principal by approximately $64.7 million.
- Cash flow from investing was positive $8.9 million, including $13.5 million net proceeds from the Oakville property sale and $4.6 million of capital expenditures. Financing used $19.7 million, including a $12.5 million Novitium earn-out payment and $8.7 million of shares withheld for employee tax obligations.
Changes and unusual items
- Rare-disease sales drove much of the revenue increase as Cortrophin Gel progressed through its third launch year. Management also cited base-business volume and new generic launches.
- Net income included a $9.7 million unrealized gain on ANI’s CG Oncology shares, recognized after CG Oncology’s IPO, and a $5.3 million gain on sale of the former Oakville site. These items materially contributed to reported earnings and are not operating sales.
- Research and development expense increased 77.4% to $10.5 million, including approximately $2.0 million for an FDA filing fee. Selling, general, and administrative expense increased 31.7% to $48.0 million, reflecting personnel costs, rare-disease commercial investment, legal expenses, and increased business activity.
- Net interest expense declined to $4.6 million from $7.7 million, principally because of higher interest and dividend income on cash balances. Operating cash flow fell year over year despite higher net income, with working-capital movements and noncash gains affecting the comparison.
- The Oakville, Ontario property sale closed March 28, 2024. ANI received approximately $13.5 million net after costs; no restructuring expense was recorded in Q1 2024.
Outlook, risks, and contingencies
- The filing provides no specific quarterly or full-year revenue, earnings, or other financial guidance. Management said cash, expected operating collections, and available credit should fund working capital and debt obligations for at least the next 12 months.
- Management’s strategy is to grow Cortrophin Gel and the rare-disease platform, develop and launch generic products, and pursue complementary acquisitions or other strategic transactions. It notes that favorable supply-disruption opportunities may not persist and that generic competition can pressure pricing.
- Key exposures include dependence on a limited number of API suppliers—one supplier represented approximately 25% of raw-material purchases in Q1—and customer concentration: four customers each represented at least 10% of revenue, and together accounted for 81% of net accounts receivable.
- Legal matters include the Bystolic antitrust appeal; ANI’s royalty dispute with CG Oncology, which has asserted counterclaims; Acella’s thyroid-product advertising lawsuit and ANI’s counterclaims; pitolisant patent litigation; and ranitidine-related proceedings. The filing says outcomes and potential losses are uncertain and does not provide a clear estimate of reasonably possible losses for the described matters.
- Four marketed products without approved NDAs or ANDAs generated $4.1 million of Q1 commercial revenue; FDA enforcement could require approval applications or withdrawal. Other risks include regulatory and approval requirements, product commercialization, competition, intellectual property, and litigation.
Important facts for investors to verify
- How much of revenue growth and future profitability depends on continued Cortrophin Gel volume and successful expansion into additional markets.
- Underlying earnings excluding the $9.7 million investment mark-to-market gain and $5.3 million property-sale gain, as well as the timing and cash impact of increased commercial and R&D spending.
- Debt-service capacity at the 11.44% term-loan rate, refinancing or maturity plans for the large 2027 principal payment, and compliance with credit-facility covenants.
- Customer and single-source supplier concentration, inventory levels, and the potential impact of pricing competition or supply interruptions.
- Developments in the disclosed lawsuits and regulatory matters, including any material settlement, loss estimate, or change in the status of unapproved products.